Drugs / MB-110
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02617615 | Dec 2017 → Jun 2018 | chronic hepatitis C virus infection | Microbio Co Ltd | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MB-110 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02617615 ↗ |
| Action | Inhibit | “HCV inhibitor against the NS5A protein.” NCT02617615 ↗ |
| Route | Oral | “multiple oral doses of MB-110” NCT02617615 ↗ |